Last reviewed · How we verify
CT Gel
CT Gel is a Topical antimicrobial agent Small molecule drug developed by Stiefel, a GSK Company. It is currently in Phase 3 development for Bacterial skin infections or colonization (specific indication pending phase 3 completion).
CT Gel is a topical antimicrobial gel formulation designed to reduce bacterial colonization and biofilm formation on skin surfaces.
CT Gel is a small molecule modality, specifically a compound known as CT 2584. It is being studied in various clinical trials for conditions including acute stroke, hypertensive intracerebral hemorrhage, prostate cancer, and metastatic castration-resistant prostate cancer.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Stiefel, a GSK Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CT Gel |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Drug class | Topical antimicrobial agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
CT Gel likely contains chlortetracycline or a similar broad-spectrum antimicrobial agent in a gel vehicle optimized for topical delivery. The formulation is intended to provide sustained antimicrobial activity against pathogenic bacteria while maintaining skin tolerability for chronic or recurrent infections.
Approved indications
- Bacterial skin infections or colonization (specific indication pending phase 3 completion)
Common side effects
- Local skin irritation
- Contact dermatitis
- Erythema
Key clinical trials
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors (PHASE2)
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (PHASE2)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (PHASE3)
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
- Decision Making in Chronic Pain and Alcohol Use Disorder (NA)
- An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT Gel CI brief — competitive landscape report
- CT Gel updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI
Frequently asked questions about CT Gel
What is CT Gel?
How does CT Gel work?
What is CT Gel used for?
Who makes CT Gel?
What drug class is CT Gel in?
What development phase is CT Gel in?
What are the side effects of CT Gel?
Related
- Drug class: All Topical antimicrobial agent drugs
- Manufacturer: Stiefel, a GSK Company — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Bacterial skin infections or colonization (specific indication pending phase 3 completion)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing